and TSH 620 mU/l (normal 1-15).
In contrast to our patients, most cases previously described were long term hypothyroid or on sporadic thyroxine replacement with excessive stimulation of TSH. Our patients unexpectedly developed true adenomas despite strict clinical and biochemical follow up, suggesting sensitivity of the patients' thyroid follicles to the effects of normal TSH concentrations. This is supported by the histological observation of diffuse hyperplasia in cases 2 and 3 as well as the presence of multiple small adenomas in case 3. Recent evidence suggests that there are many other thyroid growth promoting agents including vasoactive inhibitory peptide4 and epidermal growth factor.5
We conclude that although patients with congenital goitrous hypothyroidism are partially protected from the development of nodular goitre by adequate thyroxine replacement treatment, they remain at risk of developing 
